SymlinPen Offers Convenient SYMLIN Administration for Enhanced Glucose Control
SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/
Amylin Pharmaceuticals, Inc.(Nasdaq: AMLN) announced today the availability of the SymlinPen(TM) 120 and the SymlinPen(TM) 60 pen-injector devices for administering SYMLIN(R)(pramlintide acetate) injection. These new pre-filled pen-injector devices feature simple, fixed dosing to improve mealtime glucose control.
A patent for low dose Glucogon
SAN FRANCISCO, Jan. 8 /PRNewswire/ -- DiObex, Inc., a privately
heldbiotechnology company developing treatments for metabolic diseases, announcedtoday that it has secured a critical patent from the U.S. Patent and TrademarkOffice for the use of very low dose glucagon, or DIO-901, in the prevention ofinsulin-induced hypoglycemia in diabetes patients. The patent grants DiObexexclusive rights to methods of reducing the risk of hypoglycemia in diabetespatients being treated with insulin by administering very low doses ofglucagon. "This patent protection strengthens our commitment to delivering the firstproduct to the market for the prevention of insulin-induced hypoglycemia indiabetes," CEO David Cory said. "DIO-901 is the only therapeutic indevelopment to prevent insulin-induced hypoglycemia, which is known to limitoptimal glycemic control and cause recurring medical
complications in mostpeople with type 1 diabetes, in many with type 2 diabetes, and is sometimesfatal."
So haven't people been using low doses of glucogon all along? How do you get a patent for what people are alredy doing. I wonder if this has implications for a closed loop artificial pancreaus. I would think that providing glucogon could be part of the program.
Does anyone know more about this?